Analytical goal setting in aneuploidy screening: Within person biological variability of first trimester biochemical markers

Prenatal Diagnosis

Volumn 33, Issue 2, 2013, Pages 124-129

  Spencer, Kevin ^a   Cowans, Nicholas J ^a  

^a KING GEORGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADOLESCENT; ADULT; AFRICAN CARIBBEAN; ANALYTICAL EQUIPMENT; ANEUPLOIDY; ARTICLE; ASIAN; BLOOD SAMPLING; BODY WEIGHT; CAUCASIAN; CLINICAL FEATURE; CONTROLLED STUDY; ETHNICITY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNAL SERUM; MEASUREMENT ACCURACY; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL SCREENING; PRIORITY JOURNAL; TRISOMY 13; TRISOMY 18; TRISOMY 21;

ADOLESCENT; ADULT; ANEUPLOIDY; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; YOUNG ADULT;

EID: 84873247296     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4019     Document Type: Article

References (30)

1. Wright D, Spencer K, Kagan KO, et al. First trimester combined screening for trisomy 21 at 7-14 weeks' gestation. Ultrasound Obstet Gynecol 2010;36:404-11.
2. Wright D, Kagan KO, Molina FS, et al. A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 2008;31:376-83.
3. Spencer K, Souter V, Tul N, et al. A screening program for Trisomy 21at 10-14 weeks using fetal nuchal translucency, maternal serum free beta hCG and PAPP-A. Ultrasound Obstet Gynaecol 1999:13;231-7.
4. Nicolaides KH, Spencer K, Avgidou K, et al. Multicenter study of first trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 2005;25:221-6.
5. Kagan KO, Wright D, Baker A, et al. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 2008;31:618-24.
6. Kagan KO, Wright D, Spencer K, et al. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008;31:491-502.
7. Cotlove E, Harris EK, William GZ. Components of variation in long term studies of serum constituents in normal subjects. III. Physiological and medical implications. Clin Chem 1970;16:1028-32.
8. Stockl D, Baadenhuijsen H, Fraser CG, et al. Desirable routine analytical goals for quantities assayed in serum. Eur J Clin Chem Clin Biochem 1995;33:157-69.
9. Holding S, Cuckle H. Maternal serum screening for Down's syndrome taking account of the results of a previous pregnancy. Prenat Diagn 1994;14:321-2.
10. Spencer K. Between pregnancy biological variability of maternal serum alpha fetoprotein and free beta hCG: implications for Down syndrome screening in subsequent pregnancies. Prenat Diagn 1997;17:39-45.
11. Spencer K. Between pregnancy biological variability of first trimester markers of Down syndrome: implications for screening in subsequent pregnancies. Prenat Diagn 2001;21:445-7.
12. Spencer K. Between pregnancy biological variability of first trimester markers of Down syndrome and the implications for screening in subsequent pregnancies: an issue revisited. Prenat Diagn 2002;22:874-6.
13. Wright D, Syngelaki A, Birdir C, et al. First-Trimester Screening for Trisomy 21 with Adjustment for Biochemical Results of Previous Pregnancies. Fetal Diagn Ther 2011;30:194-202.
14. Cuckle HS, Densem J, Wald NJ. Repeat maternal serum testing in multiple marker Down's syndrome screening programmes. Prenat Diagn 1994;14:603-7.
15. Hackshaw AK, Densem J, Wald NJ. Repeat maternal serum testing for Down's syndrome screening using multiple markers with special reference to free α and free β-hCG. Prenat Diagn 1995;15:1125-30.
16. Spencer K, Cuckle HS. Screening for chromosomal anomalies in the first trimester: does repeat maternal serum screening improve detection rates? Prenat Diagn 2002;22:903-6.
17. Evans MI, Hallahan TW, Krantz D, Galen RS. Meta-analysis of first trimester Down syndrome screening studies: free beta-human chorionic gonadotropin significantly outperforms intact human chorionic gonadotropin in a multimarker protocol. Am J Obstet Gynecol 2007;196:198-205.
18. Spencer K, Spencer CE, Power M, et al. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. BJOG 2000;107:1271-5.
19. Spencer K, Spencer CE, Power M, et al. Screening for chromosomal anomalies in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. BJOG 2003;110:281-6.
20. Spencer K, Cowans NJ, Uldberg N, et al. First trimester intact hCG as an early marker of trisomy 21: a promise unrecognised? Prenat Diagn 2008;28:1156-9.
21. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989;27:409-37.
22. Fraser CG, Petersen PH. Analytical performance characteristics should be judged against objective quality specifications. Clin Chem 1999;45:321-3.
23. Klee GG. Establishment of outcome-related analytic performance goals. Clin Chem 2010;56:714-22.
24. Fraser CG. Biological Variation: From Principles to Practice. Washington, DC: AACC Press; 2001.
25. Benn PA, Collins R. Evaluation of effect of analytical imprecision in maternal serum screening for Down's syndrome. Ann Clin Biochem 2001;38:28-36.
26. Spencer K. Evaluation of effect of analytical imprecision in maternal serum screening for Down's syndrome. Ann Clin Biochem 2001;38:413-4.
27. Spencer K. Risk, a QC parameter. Down's Screening News 2003;10:30-1.
28. https://results.ukneqas.org.uk/output/EDI/Down's%201st%20T%202010%20[SAG]%20Edited.pdf.
29. http://www.fetalmedicine.com/fmf/FMF%20Certification%20of%20Biochemical%20Laboratories_new.pdf.
30. Wright D, Abele H, Baker A, Kagan KO. Impact of bias in serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A multiples of the median levels on first-trimester screening for trisomy 21. Ultrasound Obstet Gynecol 2011;38:309-13.